Adaptive Biotechnologies ... (ADPT)

Adaptive Biotechnologies (ADPT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Here is how Adaptive Biotechnologies (ADPT) and CVS Health (CVS) have performed compared to their sector so far this year.

Here is how Adaptive Biotechnologies (ADPT) and CVS Health (CVS) have performed compared to their sector so far this year.

Does Adaptive Biotechnologies (ADPT) have what it takes to be a top stock pick for momentum investors? Let's find out.

The consensus price target hints at a 26.5% upside potential for Adaptive Biotechnologies (ADPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in e...

Here is how Adaptive Biotechnologies (ADPT) and Centene (CNC) have performed compared to their sector so far this year.

Adaptive Biotechnologies Corporation (NASDAQ:ADPT ) Q1 2025 Earnings Conference Call May 1, 2025 4:30 PM ET Company Participants Karina Calzadilla - Head of Investor Relations & FP&A Chad Robins - Chi...

The headline numbers for Adaptive Biotechnologies (ADPT) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wal...

Adaptive Biotechnologies (ADPT) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.33 per share a year ago.